Previous 10 | Next 10 |
Novavax Presents Data on Updated COVID-19 Vaccine and Progress to Date on its COVID-19-Influenza Combination Vaccine Candidate at World Vaccine Congress 2024 PR Newswire GAITHERSBURG, Md. , April 1, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global comp...
2024-03-09 01:59:00 ET Investing basics tell us to "buy low" and invest in a stock when there looks to be significant upside potential. That can often be after a company gets put through the wringer and the stock declines substantially. However, sometimes it's not worth investing in a compa...
2024-03-07 13:29:15 ET More on AstraZeneca, CSL, etc. Sanofi (SNY) TD Cowen 44th Annual Health Care Conference (Transcript) GSK Plc: An Undervalued Vaccine Behemoth That Is Resuming Growth; Buy CSL Limited: Earnings Beat Doesn't Mask Unfavorable Trial Results (Downgr...
2024-03-06 16:43:13 ET Novavax, Inc. (NVAX) TD Cowen's 44th Annual Health Care Conference Call March 06, 2024, 1:30 PM ET Company Participants John Jacobs - President and Chief Executive Officer Filip Dubovsky - President, Research and Development Jim Kelly - Exe...
2024-03-05 08:09:09 ET More on BioNTech, Moderna, etc. Pfizer Inc. (PFE) TD Cowen 44th Annual Health Care Conference 6%-Yielding Pfizer Is An Ultra-Deep-Value Gem In An Expensive Market Novavax: Another Day Older And Deeper In Biden to launch task force to ta...
2024-03-04 05:03:00 ET Novavax (NASDAQ: NVAX) has taken investors on a roller coaster ride over the past week or so. The stock soared after the company settled a dispute with a big customer, then sank as it reported lower-than-expected earnings. The vaccine maker has struggled t...
2024-03-01 05:25:00 ET Since 2021, shares of Novavax (NASDAQ: NVAX) have absolutely crumbled, falling by a whopping 95%. Even with the price rally in recent days, the stock has still been a disastrous investment over the past few years. The price drop was justified largely because t...
Novavax to Participate in TD Cowen's 44th Annual Health Care Conference PR Newswire GAITHERSBURG, Md. , Feb. 29, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today an...
Novavax Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights PR Newswire Achieved revenues in Q4 2023 of $291 million and full year 2023 of $1.0 billion Accelerating progress toward expanding pipeline via Phase 3 COVID-19...
SilverBow Resorces Inc. (SBOW) is expected to report $2.36 for Q4 2023 FAT Brands Inc. Class B Common Stock (FATBB) is expected to report for quarter end 2023-12-31 Ecovyst Inc. (ECVT) is expected to report $0.2 for Q4 2023 MYR Group Inc. (MYRG) is expected to report $1.41 for Q4 2023...
News, Short Squeeze, Breakout and More Instantly...
Novavax Submits Application to Health Canada for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine Canada NewsWire Novavax's COVID-19 vaccine would be the only protein-based option available in Canada , if authorized Novavax's filing is aligned with NACI, ...